StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences AmBisome (liposomal amphotericin B by Quarter

AmBisome (liposomal amphotericin B — systemic antifungal) ($M) ($M)

Gilead Sciences AmBisome (liposomal amphotericin B: $110M in Q2 2026, down 14.7% from a year earlier.

Latest, Q2 2026
110
Period ended Jun 30, 2026
Change on a year earlier
-14.7%
129 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
30
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAmBisome (liposomal amphotericin B — systemic antifungal) ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026110-14.7%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 2026138-0.7%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 2025118+8.3%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025123-5.4%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 2025129-14.6%Form 10-Q (filed 2026-08-06) ↗
Q1 2025Mar 31, 2025139-3.5%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 2024109-1.8%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024130+13.0%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 20241510.0%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024144+24.1%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 2023111-5.1%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 2023115+9.5%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 2023151+14.4%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023116-19.4%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022117-2.5%Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 2022105-26.6%Form 10-Q (filed 2023-11-07) ↗

Breakdown

What makes up amBisome (liposomal amphotericin B

Cite this data

StockData. (2026). Gilead Sciences AmBisome (liposomal amphotericin B ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other-ambisome

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.